Loading
A phase 1 trial of TLN-372 run by Treeline Biosciences, Inc., now recruiting.
TLN-372 in Advanced KRAS Mutant Solid Tumors is a phase 1 interventional study registered as NCT07204340 by Treeline Biosciences, Inc., with 270 participants planned, started 2025-09-29. Conditions recorded: KRAS Mutant Solid Tumors. Interventions recorded: TLN-372, TLN-372 in combination with cetuximab and TLN-372 in combination with pembrolizumab.
Shares Treeline Biosciences and the tag pipeline.
Shares Treeline Biosciences and the tag pipeline.
Shares Treeline Biosciences and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/